About: FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity
Creator	Berger, Annemarie Ciesek, Sandra Hoehl, Sebastian Schmidt, Michael Seifried, Erhard Hourfar, Kai Zeichhardt, Heinz
Source	MedRxiv
abstract	Background: In the pandemic, testing for SARS-CoV-2 by RT-PCR in one of the pillars on which countermeasures are based. Factors limiting the output of laboratories interfere with the effectiveness of public health measures. Conserving reagents by pooling samples in low-probability settings is proposed, but may cause dilution and loss of sensitivity. Methods: We tested an alternate approach (FACT) by simultaneously incubating multiple respiratory swabs in a single tube. This protocol was evaluated by serial incubation of a respiratory swab in up to 10 tubes. The analytics validity of this concept was demonstrated in a five-sample mini pool set-up. It was consequently applied in the testing of 50 symptomatic patients (five-sample pools) as well as 100 asymptomatic residents of a nursing home (ten-sample pools). Results: Serial incubation of a respiratory swab in up to 10 tubes did not lead to a significant decline in viral concentration. The novel FACT-protocol did not cause a false negative result in a five-sample mini-pool setup, with non-significantly differing Ct values between single sample and mini-pool NAT. In two routine applications, all mini pools containing positive patient samples were correctly identified. Conclusions: Our proposed FACT- protocol did not cause a significant loss in analytic or diagnostic sensitivity compared to single sample testing in multiple setups. It reduced the amount of reagents needed by up to 40%, and also reduced hands-on time. This method could enhance testing efficiency, especially in groups with a low pretest-probability, such as systemically relevant professional groups.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.1101/2020.04.28.20074187
has license	medrxiv
sha1sum (hex)	502a07aa4640266d17066eb92c79e6fdc79b923a
schema:url	https://doi.org/10.1101/2020.04.28.20074187
resource representing a document's title	FACT- Frankfurt adjusted COVID-19 testing- a novel method enables high-throughput SARS-CoV-2 screening without loss of sensitivity
resource representing a document's body	covid:502a07aa4640266d17066eb92c79e6fdc79b923a#body_text
is schema:about of	named entity 'loss' named entity 'EFFECTIVENESS' named entity 'PUBLIC HEALTH' named entity 'samples' named entity 'dilution' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'public health' named entity 'RT-PCR' named entity 'loss of sensitivity' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'p-value' named entity 'SARS-CoV-2' named entity 'gene' named entity 'WHO' named entity 'ORF' named entity 'throat swab' named entity 'viral load' named entity 'gene' named entity 'Roche Diagnostics' named entity 'COVID-19' named entity 'preprint' named entity 'COVID' named entity 'May 1' named entity 'doi' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'infection' named entity 'virus' named entity 'clinical diagnosis' named entity 'preprint' named entity 'SARS' named entity 'preprint' named entity 'asymptomatic' named entity 'virus' named entity 'incubation' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2 pandemic' named entity 'preprint' named entity 'negative result' named entity 'ORF' named entity 'medRxiv' named entity 'infection' named entity 'preprint' named entity 'peer review' named entity 'May 1' named entity 'clinical symptoms' named entity 'preprint' named entity 'health care workers' named entity 'WNV' named entity 'P-value' named entity 'HIV-1' named entity '4.3' named entity 'WHO' named entity 'preprint' named entity 'medRxiv' named entity 'gene' named entity 'SARS-CoV-2' named entity 'statistically significant' named entity 'buffer solution' named entity 'infection' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'virus' named entity 'guanidinium thiocyanate' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'Frankfurt' named entity 'medRxiv' named entity 'SARS-CoV-2 virus' named entity 'ORF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software